: 2020.6.4 목 20:08
Clinical 학술 Selection
Medi pharm IN
Boehringer Ingelheim launches RE-VECTO global program to capture data on Praxbind usage in clinical practice
Boehringer Ingelheim launches RE-VECTO global program to capture data on Praxbind® usage in clinical practice Praxbind® ...
Takeda Receives Marketing Authorization in Canada for NINLARO in Relapsed·Refractory Multiple Myeloma
Takeda Pharmaceutical Company Limited (TSE:4502) today announced Takeda Canada has received approval from Health Canada ...
Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma
Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin...
Boehringer Ingelheim and University of Dundee collaborate to develop new class of medicines
INGELHEIM, GERMANY & DUNDEE, SCOTLAND--(Business Wire/Korea Newswire) July 15, 2016 -- Scotland--(BUSINESS WIRE)-- Boehr...
ASTRAZENECA’S COMBINATION OF DURVALUMAB WITH TREMELIMUMAB SHOWS CLINICAL ACTIVITY IN NON-SMALL CELL LUNG CANCER IRRESPECTIVE OF PD-L1 STATUS
LONDON--AstraZeneca and MedImmune, its global biologics research and development arm, today announced publication in The...
Takeda and enGene Establish Strategic Alliance to Develop Novel Therapeutics for Gastrointestinal Diseases
Takeda Pharmaceutical Company Ltd. (TOKYO:4502) (http://goo.gl/eX9kbP) and enGene, Inc. today announced a strategic alli...
Boehringer Ingelheim Invests in Europe: Pharma Company Expands Biopharmaceutical Production at Vienna Site
Boehringer Ingelheim will make a significant investment in biopharmaceutical production at its Vienna (Austria) site. Th...
Merck and Pfizer Initiate Two Phase III Studies of Investigational Immunotherapy Avelumab in Advanced Gastric and Gastro-esophageal Junction Cancers
Merck and Pfizer today announced the initiation of two Phase III studies of avelumab*, an investigational, fully human a...
Takeda Presents Data from Phase 3 TOURMALINE-MM1 Study for NINLARO, First and Only Once-Weekly Oral Proteasome Inhibitor Recently Approved for Multiple Myeloma
Takeda Pharmaceutical Company Limited (TSE:4502, http://goo.gl/eX9kbP) today announced results from the TOURMALINE-MM1 t...
Merck and Pfizer Announce FDA Orphan Drug Designation for Investigational Immunotherapy Avelumab in Merkel Cell Carcinoma
Merck and Pfizer today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation for ...
Jardiance demonstrated cardiovascular risk reduction in people with type 2 diabetes at high risk for CV events
Boehringer Ingelheim and Eli Lilly and Company today announced positive top-line results from EMPA-REG OUTCOME®. This is...
European Medicines Agency Grants Accelerated Assessment of Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the Committee for Medicinal Products for Human Us...
Boehringer Ingelheim enters into an exclusive license agreement with Hanmi Pharmaceutical to develop 3rd generation EGFR targeted therapy in lung cancer
Boehringer Ingelheim and Hanmi Pharmaceutical Co. Ltd today announced an exclusive license and collaboration agreement f...
Efficacy Results of Otsuka’s Delamanid (Deltyba) for Extensively Drug-Resistant Tuberculosis (XDR-TB) Published in the New England Journal of Medicine
Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that data from a post-hoc subset analysis of its Phase IIb clin...
Type 2 diabetes: Patients reporting better quality of communication by their physician show improved self-care
Type 2 diabetes: Patients reporting better quality of communication by their physician show improved self-care New resea...
Hakim Djaballah, CEO of Institut Pasteur Korea, responds to comments made on the current MERS-CoV situation in Korea
Hakim Djaballah, CEO of Institut Pasteur Korea, responds to comments made on the current MERS-CoV situation in Korea. Pa...
Boehringer Ingelheim and Lilly Diabetes Alliance to Present Data from 35 Studies at the American Diabetes Association’s® 75th Scientific Sessions
The presentation of 35 abstracts will demonstrate the breadth and depth of the Boehringer Ingelheim and Eli Lilly and Co...
Merck and Pfizer to Present Data at ASCO for Avelumab, an Investigational Anti-PD-L1 Antibody
DARMSTADT, GERMANY & NEW YORK--(Business Wire/Korea Newswire) May 14, 2015 -- Merck and Pfizer today announced multiple ...
Hydra Biosciences and Boehringer Ingelheim Enter Research Collaboration Focused on Renal Diseases and Disorders
Hydra Biosciences, Inc., a leader in the field of transient receptor potential (TRP) channel modulation, and Boehringer ...
the First Interim Analysis of the Phase 3 Study of Oral Ixazomib in Patients with Relapsed or Refractory Multiple Myeloma Met the Primary Endpoint of Improvement in Progression-Free Survival
CAMBRIDGE, MASS. & OSAKA, JAPAN--(Business Wire/Korea Newswire) February 10, 2015 -- Takeda Pharmaceutical Company Limit...
명칭 : (주)메디컬헤럴드
정기간행물 등록번호 : 서울 아 00603
등록일 : 2008년 6월 23일
제호 : 메디컬헤럴드(The Medical Herald)
발행·편집인 : 우정헌
주소: (우 06178) 서울특별시 강남구 테헤란로 84길 14 지어로빌딩 10층
발행일 : 2008년 4월 1일
전화 : 02-555-7482
팩스 : 02-565-0938
청소년보호책임자 : 우정헌
(우)05836 서울 송파구 법원로 9길 26 1017호 메디컬 미디어 연구소(에이치비지니스파크, 문정동)
2020 메디컬헤럴드. All rights reserved.
Back to Top